Bupivacaine HCl Injection, single dose vial, Preservative Free 0.5%, 10mL (25/ct), Rx only, Manufacturer: Auromedics Pharma LLC, NDC 55150-169-10
Published June 15, 2022 · Recall initiated: April 13, 2022
Summary
FDA records drug Class II recall D-0998-2022, published June 15, 2022 and initiated April 13, 2022. Recalling firm: Mckesson Medical-Surgical Inc. Corporate Office; Status: Terminated; Reported quantity: 224 cartons/10 vials each; Lot: McKesson Medical-Surgical (MMS) is not able to identify the particular lot number received by a particular consignee for the recalled prescription products. Each letter includes the date it was distributed to customers and the dates that impacted product may have been shipped to the customer. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.
Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.
What's the hazard
cGMP deviations: Temperature abuse
What to do
Voluntary: Firm initiated · Letter
Get an email if BUPIVACAINE HYDROCHLORIDE has another recall
Free. We only write when there's a new recall that matches. Unsubscribe in one click.
Recall details
- Brand
- BUPIVACAINE HYDROCHLORIDE
- Manufacturer
- Mckesson Medical-Surgical Inc. Corporate Office
- Distributor
- USA nationwide.
- UPC
- 0355150170302
- Lot
- McKesson Medical-Surgical (MMS) is not able to identify the particular lot number received by a particular consignee for the recalled prescription products. Each letter includes the date it was distributed to customers and the dates that impacted product may have been shipped to the customer.
- Risk classification
- Class II
- Area (FDA)
- drug
- Country
- United States
Related recalls
- FDABupivacaine Hydrochloride 0.75% in 8.25% Dextrose Injection, USP (15 mg/2 mL) (7.5 mg/mL) ampules, Rx only,April 22, 2026
- FDABupivacaine Hydrochloride, USP 0.5% (5mg/mL), 25 vials x 50 mL per box, Rx only, MFG: Pfizer, NDC 0409-1163-01June 15, 2022
- FDAAzithromycin for Injection USP Vial, 500 mg per vial, Rx only, Manufacturer: Auromedics Pharma LLC, NDCJune 15, 2022
- FDABupivacaine HCl Injection, single dose vial, 0.5%, 30 mL/5 mg/mL, Rx only, Manufacturer: Auromedics PharmaJune 15, 2022
- FDABupivacaine Hydrochloride Inj., USP (2.5 mg/mL) 0.25%, packaged in 30 mL Single-dose Preservative-Free vials,December 28, 2016
- FDABupivacaine HCl Inj., USP, 0.5% (5 mg/mL), 30 mL Single-dose Preservative-Free, For Nerve Block, Caudal, andSeptember 24, 2014
Questions about this recall
Was Bupivacaine HCl Injection, single dose vial, Preservative Free 0.5%, 10mL (25/ct), Rx only, Manufacturer: Auromedics Pharma LLC, NDC 55150-169-10 recalled?
Yes. FDA published recall D-0998-2022 on June 15, 2022. Reported hazard: cGMP deviations: Temperature abuse
What should I do if I have this product?
Voluntary: Firm initiated · Letter
How do I know if my unit is part of the recall?
Compare your product details with the notice. Brand: BUPIVACAINE HYDROCHLORIDE. UPC: 0355150170302.